Celltrion announced on March 25 that it has received a recommendation for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) for the full label of its Xolair (active ingredient: omalizumab) biosimilar “CT-P39.”The original
Samsung Bioepis announced on Feb. 25 that it has obtained a positive opinion for the sale of its biosimilar of Stelara, known as Pyzchiva, from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA).The original drug of Pyzchiva developed by Janssen, know
Kang Stem Biotech announced on Jan. 24 that it received final approval from the Japanese Ministry of Health, Labour and Welfare on Jan. 23 for its application for recognition of the manufacture of specific cell processed products.Through this approval, the company will receive adipose tissue from pa
According to the BioEconomy Research Center of the Korea Biotechnology Industry Organization on Jan. 10, WuXi Biologics, a leading Chinese biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is confirmed to be constructing a commercial biopharmaceutical raw material product
Samsung C&T Corporation, along with its subsidiaries Samsung Biologics and Samsung Bioepis, announced on Jan. 9 the signing of a memorandum of understanding (MOU) for strategic cooperation with the U.S.-based Flagship Pioneering through their jointly established Life Science Fund No. 2 (SVIC 64th Ne
Dong-A ST announced on Jan. 4 that it has signed a license-in agreement with SK Biopharmaceuticals to license out its new epilepsy drug Cenobamate in 30 countries including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkiye.Under the agreement, Dong-A ST will receive dr
On Dec. 28, the integrated company Celltrion will be officially launched. Celltrion is taking steps to leap into a global big pharmaceutical firm by merging with Celltrion Healthcare, which is responsible for global distribution.Celltrion and Celltrion Healthcare announced on Dec. 27 that they are i
A top European Commission (EC) official has given a positive assessment for the first time to remedial measures submitted by Korean Air to the EC for its merger with Asiana Airlines.“We have seen very positive progress on some of the proposals in Korean Air’s remedial measures,” EC Justice Commissio
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be h
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company’s board of directors has decided to invest in the expansion of L HOUSE, a vaccine manufacturing plant of SK bioscience located in Andong, South Korea to ap
McKinsey introduced the content of its report, “Koreas Next S-Curve,” to international media outlets at Shilla Hotel in Seoul on Oct. 19. In the report, the company proposed three pillars of reorganization, transformation, and construction and eight action items for Korea’s economic renaissance.McKi
SK pharmteco will participate at the CPHI 2023 in Barcelona and prepare a dedicated booth at the event. As a multi-modality CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pu
As the patent for the blockbuster pharmaceutical “Stelara,” which generated more than 23 trillion won (US$17.1 billion) in global sales last year, approaches expiration, domestic biosimilar developers are consistently announcing their clinical trial results. Biosimilars refer to replica drugs develo
Domestic hedge fund and private equity firm Brain Asset Management has embarked on a US$500 million (675 billion won) pre-IPO investment in SK pharmteco, which involves investing in the company’s equity before it goes public. Following an initial investment of US$300 million (405 billion won), it ha
The operating profit of South Korea’s top 100 companies in the first half of this year showed a significant deterioration compared to the top 100 companies in the United States. In particular, for the two largest companies by market capitalization in both countries, Apple and Samsung Electronics, wh
SK pharmteco, the Contract Development and Manufacturing Organization (CDMO) subsidiary of SK, announced on Sept. 20 that it has acquired The Center for Breakthrough Medicines (CBM), a U.S.-based Cellular and Gene Therapy (CGT) CDMO.Last January, SK pharmteco invested US$350 million in CBM to streng
Samsung Biologics announced on Sept. 18 that it has signed a contract manufacturing organization (CMO) agreement worth US$242 million (321.3 billion won) with BMS. The agreement entails the supply of biopharmaceuticals to BMS over the next seven years, extending until 2030.BMS, ranked 7th globally i
The government is set to invest 400 billion won (US$301.66 million) next year and a total of 2.2 trillion won over the next five years to establish geographical zones dedicated to creating specific industries at world-class level. To boost the venture ecosystem, it plans to increase the external fun
As of April this year, South Korea has emerged as one of the top three external importers of the European Union (EU). Excluding European countries, South Korea has secured the third position in this ranking, following China and the United States. This marks the first time that South Korea has surpas
TiumBio Co., Ltd. (KRX: 321550. KQ), a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for patients with rare and incurable diseases, today announced that the Phase 1a results of TU2218 will be presented at the 2023 European Society of Medical